- A 21-subject Phase 1/2 study evaluating Targacept's (TRGT -2.9%) TC-6499 for the treatment of diabetic gastroparesis failed to achieve its primary endpoint, a change in gastric emptying time compared to placebo. Based on the results, the company will not pursue further development of TC-6499 for this indication.
- Gastroparesis is a condition in which the spontaneous movement of the stomach muscles (motility) is weak or nonfunctional. This prevents the stomach from emptying properly which interferes with normal digestion, increases blood sugar levels and causes nausea and vomiting.
- TC-6499 is a small molecule that modulates neuronal nicotinic receptors, including alpha3beta4, which is found throughout the GI tract. Motility is (supposedly) increased when it is stimulated.